BUENA, N.J., June 26, 2014 /PRNewswire/ -- IGI
Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today
announced that it is offering shares of the Company's common stock
in an underwritten public offering. The proposed offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Roth Capital Partners and Oppenheimer & Co. are acting as
joint book-running managers for the proposed offering.
The Company intends to use the net proceeds from this offering
for general corporate purposes, including, without limitation,
research and development, general and administrative, manufacturing
and marketing expenses, and potential not yet identified
acquisitions of companies, products, ANDAs, technologies and assets
that complement the Company's business.
The shares described above are being offered pursuant to a
registration statement previously filed with and subsequently
declared effective by the Securities and Exchange Commission (SEC).
A preliminary prospectus supplement relating to the offering will
be filed with the SEC and will be available on the SEC's website at
http://www.sec.gov. The final terms of the offering will be
disclosed in a final prospectus supplement filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Copies of the preliminary prospectus supplement and accompanying
base prospectus relating to this offering may be obtained by
sending a request to Roth Capital Partners, LLC, 888 San Clemente
Drive, Newport Beach, California
92660, (800) 678-9147 or to Oppenheimer & Co. Attention:
Syndicate Prospectus Department, 85 Broad Street, 26th Floor,
New York, NY 10004, or by
telephone at (212) 667-8563, or by email at
EquityProspectus@opco.com.
About IGI Laboratories, Inc.
IGI Laboratories is a generic topical pharmaceutical company. We
develop and manufacture topical formulations for the
pharmaceutical, OTC, and cosmetic markets. Our mission is to be a
leading player in the generic topical prescription drug market.
Forward-Looking Statements
This press release includes certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, plans, objectives, expectations and intentions, and
other statements contained in this press release that are not
historical facts and statements identified by words such as "plan,"
"believe," "continue", "should" or words of similar meaning.
Factors that could cause actual results to differ materially from
these expectations include, but are not limited to: our inability
to meet current or future regulatory requirements in connection
with existing or future ANDAs; our inability to achieve
profitability; our failure to obtain FDA approvals as anticipated;
our inability to execute and implement our business plan and
strategy; the potential lack of market acceptance of our products;
our inability to protect our intellectual property rights; changes
in global political, economic, business, competitive, market and
regulatory factors; and our inability to complete successfully
future product acquisitions. These statements are based on our
current beliefs or expectations and are inherently subject to
various risks and uncertainties, including those set forth under
the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
other periodic reports we file with the Securities and Exchange
Commission. IGI Laboratories, Inc. does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130827/MM70487LOGO
SOURCE IGI Laboratories, Inc.